CAS 1609392-27-9

Deucravacitinib

Description:

Deucravacitinib is a novel small molecule that functions as a selective inhibitor of the enzyme tyrosine kinase 2 (TYK2), which plays a crucial role in the signaling pathways of various cytokines involved in immune responses. This compound is primarily investigated for its therapeutic potential in treating autoimmune diseases, particularly psoriasis and other inflammatory conditions. Deucravacitinib exhibits a unique mechanism of action by selectively targeting TYK2, thereby modulating the immune response with potentially fewer side effects compared to broader immunosuppressants. Its pharmacokinetic profile suggests good oral bioavailability and a favorable half-life, allowing for convenient dosing regimens. The substance is characterized by its specific chemical structure, which contributes to its selectivity and efficacy. Ongoing clinical trials are assessing its safety, tolerability, and effectiveness in various patient populations, making it a promising candidate in the field of immunology and dermatology. As research progresses, further insights into its long-term effects and potential applications in other diseases may emerge.

Formula: C₂₀H₂₂N₈O₃

Synonyms:

• Deucravacitinib BMS986165
• 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
• 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H?)methylpyridazine-3-carboxamide
• BMS-986165
• Tyk2-IN-4
• Deucravacitinib (TYK2-IN-4
• Deucravacitinib
• TYK2-IN-4;BMS986165;BMS-986165;BMS 986165

Deucravacitinib (BMS-986165)

CAS: 1609392-27-9

Formula: C₂₀H₁₉D₃N₈O₃

Molecular weight: 425.47

Ref: 4Z-B-210001

Deucravacitinib

CAS: 1609392-27-9

Deucravacitinib

Purity: ≥98%

Molecular weight: 425.46g/mol

Ref: 54-BUP15236

Deucravacitinib

CAS: 1609392-27-9

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.

Formula: C₂₀H₁₉D₃N₈O₃

Purity: 98.52% - >99.99%

Color and Shape: Solid

Molecular weight: 425.46

Ref: TM-T14687

Deucravacitinib

Controlled Product

CAS: 1609392-27-9

Formula: C₂₀D₃H₁₉N₈O₃

Color and Shape: Neat

Molecular weight: 425.459

Ref: TR-D665481

BMS-986165

Controlled Product

CAS: 1609392-27-9

BMS-986165 is a P-glycoprotein (P-gp) inhibitor that has been shown to reduce the absorption of ciclosporin, tacrolimus, and everolimus in vitro. BMS-986165 has an activity index of 100% and inhibits the inflammatory response by inhibiting the production of cytokines. It has been found to be effective for treating bowel diseases, such as ulcerative colitis and Crohn's disease. The drug also may be used for the treatment of autoimmune diseases, such as psoriasis or rheumatoid arthritis. BMS-986165 is administered orally and is rapidly absorbed. It is metabolized by CYP3A4 and excreted in urine as metabolites. END>> END>>

Formula: C₂₀H₁₉D₃N₈O₃

Purity: Min. 95%

Molecular weight: 425.46 g/mol

Ref: 3D-JPC39227

Tyk2-IN-4

CAS: 1609392-27-9

Formula: C₂₀H₁₉D₃N₈O₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 425.4590

Ref: IN-DA01EO63